Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2025-2031

  Block, Martin ^a   Fister, Stefanie ^a   Emons, Günter ^a   Seeber, Sandrine ^a   Gründker, Carsten ^a   Günthert, Andreas R ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

AKT; Antiestrogens; EGF R; Endometrial cancer; Everolimus; Gefitinib; mTOR; Perifosine; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; AROMATASE; ESTROGEN; EVEROLIMUS; FULVESTRANT; G PROTEIN COUPLED RECEPTOR 30; GEFITINIB; GROWTH FACTOR RECEPTOR; PERIFOSINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENDOMETRIUM CANCER; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTRACELLULAR SIGNALING; MUTATION; PRIORITY JOURNAL;

APOPTOSIS; AROMATASE; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 77955081715     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Temkin SM and Fleming G: Current treatment of endometrial cancer. Cancer Control 16: 38-45, 2009.
2. Gründker C, Günthert AR and Emons G: Hormonal heterogeneity of endometrial cancer. Adv Exp Med Biol 48: 2292-2301, 2008.
3. Thigpen T, Brady MF, Homesley HD, Soper JT and Bell J: Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 15: 364-367, 2001.
4. Whitney Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R and Andersen W: Phase II study of alternating courses of megestrole acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92: 1-3, 2004.
5. Cuzick J: Future possibilities in the prevention of breast cancer: breast cancer prevention trials. Breast Cancer Res 2: 258-263, 2000.
6. Chaudhry P and Asselin E: Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer 16: 363-380, 2009.
7. Wu X, Senechal K, Neshat MS, Whang YE and Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95: 15587-15591, 1998.
8. Terakawa N, Kanamori Y and Yoshida S: Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 10: 203-208, 2003.
9. Revankar CM, Mitchell HD, Field AS, Burai R, Corona C, Ramesh C, Sklar LA, Arterburn JB and Prossnitz ER: Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol 2: 536-544, 2007.
10. Khalifa MA, Mannel RS, Haraway SD, Walker J and Min KW: Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 53: 84-92, 1994.
11. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò Sand Maggiolini M: The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20: 631-646, 2006.
12. Treeck O, Diedrich K and Ortmann O: The activation of an extracellular signal-regulated kinase by oestradiol interferes with the effects of trastuzumab on HER2 signalling in endometrial adenocarcinoma cell lines. Eur J Cancer 39: 1302-1309, 2003.
13. Pfeiler G, Horn F, Lattrich C, Klappenberger S, Ortmann O and Treeck O: Apoptotic effects of signal transduction inhibitors on human tumor cells with different PTEN expression. Oncol Rep 18: 1305-1309, 2007.
14. Albitar L, Laidler LL, Abdallah R and Leslie KK: Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors. Mol Cancer Ther 4: 1891-1899, 2005.
15. Albitar L, Pickett G, Morgan M, Davies S and Leslie KK: Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol 106: 52-64, 2007.
16. Nicoletti I, Migliorati G, Pagliacci MC, Grignani and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 159: 271-279, 1991.
17. Leblanc K, Sexton E, Parent S, Bélanger G, Déry MC, Boucher V and Asselin E: Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens. Int J Oncol 30: 477-487, 2007.
18. Wakeling AE, Dukes M and Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873, 1991.
19. O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pitot HC, Chatterton R and Jordan VC: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 90: 1552-1558, 1998.
20. Ball LJ, Levy N, Zhao X, Griffin C, Tagliaferri M, Cohen I, Ricke WA, Speed TP, Firestone GL and Leitman DC: Cell type-and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements. Mol Cell Endocrinol 299: 204-211, 2009.
21. Gu J, Tamura M and Yamada KM: Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 145: 1375-1383, 1998.
22. Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR and Sun SY: The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 6: 2029-2038, 2007.
23. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA and Roy KK: Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2: 1093-1103, 2003.
24. Engel JB, Hönig A, Schönhals T, Weidler C, Häusler S, Krockenberger M, Grunewald TG, Dombrowski Y, Rieger L, Dietl J and Wischhusen J: Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation. Eur J Obstet Gynecol Reprod Biol 141: 64-69, 2008.
25. Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Müller B, Budczies J, Röske A, Dietel M and Denkert C: Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 135: 933-941, 2009.
26. Li X, Xiao L, Yang Y, Shen H, Zeng H and Wang Z: The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells. J Huazhong Univ Sci Technolog Med Sci 28: 340-342, 2008.
27. Albitar L, Carter MB, Davies S and Leslie KK: Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer. Gynecol Oncol 106: 94-104, 2007.
28. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ and Podratz KC: Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 98: 1076-1084, 2008.